Blood Banking and Blood Products

Blood Banking and Blood Products

Global Blood Banking and Blood Products Market to Reach US$69.0 Billion by 2030

The global market for Blood Banking and Blood Products estimated at US$50.0 Billion in the year 2023, is expected to reach US$69.0 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Blood Components & Plasma Products, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$56.4 Billion by the end of the analysis period. Growth in the Equipment, Blood Tests & Other Consumables segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.2 Billion While China is Forecast to Grow at 7.4% CAGR

The Blood Banking and Blood Products market in the U.S. is estimated at US$13.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$15.3 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Blood Banking and Blood Products Market - Key Trends and Drivers Summarized

How Does the Blood Banking System Sustain Public Health?

Blood banking, a critical component of modern healthcare systems, ensures the safe collection, storage, and distribution of blood and blood products necessary for medical procedures. This system involves not only the collection of whole blood from donors but also the processing of blood to obtain components like red cells, platelets, and plasma, which can be used individually to treat various conditions. Stringent regulatory standards govern every step of the process to minimize risks of transfusion-transmitted infections and ensure the safety and effectiveness of blood products. Blood banks also play a vital role in emergency preparedness by maintaining an adequate supply to meet routine and crisis-driven demands. The efficiency of blood banks in managing the supply chain—from donor recruitment to the final delivery of blood products to medical facilities—directly impacts their ability to save lives and improve patient outcomes.

What Technological Innovations Are Enhancing Blood Banking?

The field of blood banking has benefited significantly from technological advancements that enhance the safety, efficiency, and efficacy of blood product storage and transfusion. Automated systems for blood collection and processing have standardized many procedures, reducing human error and increasing the yield of viable blood components. Technologies such as pathogen reduction systems improve the safety of blood transfusions by inactivating potential contaminants that can cause infections. Moreover, sophisticated refrigeration and freezing equipment has extended the shelf life of blood products, allowing for better management of inventories and reduced waste. Data management systems integrate these technologies, providing real-time tracking and optimized logistics, ensuring that the right type of blood product is available when and where it is needed most.

How Are Regulatory Changes and Global Health Needs Shaping Blood Banking?

Regulatory frameworks and global health needs are constantly shaping practices within the blood banking industry. Changes in regulations often reflect advancements in medical research, emerging health threats, or shifts in public health policies. For example, responses to global pandemics or outbreaks necessitate rapid adjustments in blood collection practices and donor eligibility criteria to safeguard the blood supply. Additionally, international collaboration efforts are enhancing the standards of practice worldwide, aiming to elevate blood safety and availability in under-resourced regions. These efforts include training, the establishment of standardized protocols, and support for infrastructure development in blood banks, which are critical for addressing disparities in global health care and ensuring equitable access to life-saving blood products.

What Drives the Growth in the Blood Banking and Blood Products Market?

The growth in the blood banking and blood products market is driven by several factors, including technological advancements, increased awareness of the importance of blood donation, and rising global health care demands. Technological innovations that improve the efficiency of blood collection, processing, and storage are crucial, as they enhance the overall safety and availability of blood supplies. Demographic trends, such as aging populations and the consequent rise in medical conditions that require blood transfusions, also contribute significantly to market expansion. Additionally, initiatives aimed at increasing donor participation and retention have been vital in meeting the growing demand for blood products. Campaigns that educate the public about the need for and benefits of donating blood, coupled with enhanced donor recruitment strategies, are essential for maintaining a stable blood supply. Furthermore, expanding healthcare infrastructure in emerging economies is increasing access to medical treatments that require blood products, thereby broadening the market. These factors, combined with ongoing research and development in transfusion medicine, continue to drive the dynamic growth of this critical sector.

Select Competitors (Total 209 Featured) -

• AABB
• Abbott Laboratories
• American Red Cross
• America`s Blood Centers
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• Beijing Tiantan Biological Products Co., Ltd.
• Bharat Serums and Vaccines Ltd.
• Bio Products Laboratory Ltd.
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Biotest AG
• Canadian Blood Services
• Cerus Corporation
• China Biologic Products, Inc.
• CSL Behring LLC
• Fenwal Inc.
• Fresenius Kabi AG
• Grifols S.A.
• Haemonetics Corporation
• Immucor Inc.
• Kawasumi Laboratories, Inc.
• Kedrion S.p.A.
• LFB Group
• MacoPharma SA
• New York Blood Center
• Octapharma AG
• Ortho-Clinical Diagnostics, Inc.
• Shanghai RAAS Blood Products Co., Ltd.
• Shire plc
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• Terumo BCT Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.